ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.125,51
0,00%
S&P 500
5.969,34
0,35%
US Dollar vs BRL
5,78656
-0,25%
Bitcoin
98.103,69
0,06%
Brent Oil
74,66
-0,15%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Insmed Inc (INSM)

  7. Insmed Inc (INSM) Notícias

INSM

Insmed (INSM)

Insmed Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:INSM
DataHoraFonteTítuloCódigoCompanhia
19/11/202410:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INSMInsmed Inc
07/11/202410:00PR Newswire (US)Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:INSMInsmed Inc
06/11/202410:00PR Newswire (US)Insmed To Present at November 2024 Investor ConferencesNASDAQ:INSMInsmed Inc
31/10/202408:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INSMInsmed Inc
31/10/202408:00PR Newswire (US)Insmed Reports Third-Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:INSMInsmed Inc
24/10/202417:05PR Newswire (US)Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers ListNASDAQ:INSMInsmed Inc
23/10/202409:00PR Newswire (US)Insmed Unites Across Communities Around the World During Third Annual Global Day of GoodNASDAQ:INSMInsmed Inc
17/10/202409:00PR Newswire (US)Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024NASDAQ:INSMInsmed Inc
08/10/202417:05PR Newswire (US)New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population ResultsNASDAQ:INSMInsmed Inc
16/09/202417:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INSMInsmed Inc
13/09/202417:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INSMInsmed Inc
03/09/202418:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:INSMInsmed Inc
08/08/202408:00PR Newswire (US)Insmed Reports Second-Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:INSMInsmed Inc
29/07/202409:00PR Newswire (US)Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024NASDAQ:INSMInsmed Inc
03/07/202410:03PR Newswire (US)Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis ConferenceNASDAQ:INSMInsmed Inc
27/06/202409:00PR Newswire (US)Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025NASDAQ:INSMInsmed Inc
05/06/202409:00PR Newswire (US)Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:INSMInsmed Inc
30/05/202417:05PR Newswire (US)Insmed to Host Commercial Webinar on June 4, 2024NASDAQ:INSMInsmed Inc
30/05/202417:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INSMInsmed Inc
30/05/202409:00PR Newswire (US)Insmed Announces Pricing of $650 Million Public Offering of Common StockNASDAQ:INSMInsmed Inc
28/05/202419:21PR Newswire (US)Insmed Announces Proposed $500 Million Public Offering of Common StockNASDAQ:INSMInsmed Inc
28/05/202407:30PR Newswire (US)Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with BronchiectasisNASDAQ:INSMInsmed Inc
27/05/202417:00PR Newswire (US)Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with BronchiectasisNASDAQ:INSMInsmed Inc
20/05/202417:28PR Newswire (US)Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International ConfeNASDAQ:INSMInsmed Inc
14/05/202417:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INSMInsmed Inc
09/05/202408:00PR Newswire (US)Insmed Reports First-Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:INSMInsmed Inc
07/05/202409:00PR Newswire (US)Insmed To Present at the BofA Securities Health Care Conference 2024NASDAQ:INSMInsmed Inc
25/04/202409:00PR Newswire (US)Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024NASDAQ:INSMInsmed Inc
27/03/202417:05PR Newswire (US)Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International ConferenceNASDAQ:INSMInsmed Inc
29/02/202410:00PR Newswire (US)Insmed To Present at Three March ConferencesNASDAQ:INSMInsmed Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:INSM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BHIA3
Grupo Casas Bahia ON
BOV
ATOM3
ATOMPAR ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
TELB4
TELEBRAS PN
BOV
AMER3
Americanas ON
BOV
HAPV3
HAPVIDA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados